[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615923":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":64,"collaborators":26,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":93,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise","EXPERIMENTAL","Participants will perform aerobic and resistance exercise while taking monthly tirzepatide for 16 weeks",[13,14],"Drug: Tirzepatide","Behavioral: Exercise",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard Care","ACTIVE_COMPARATOR","Participants will take monthly Tirzepatide under the care of their primary care provider for 16 weeks",[13],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tirzepatide","Participants will take tirzepatide under the care of their primary care provider for 16 weeks",[9,16],null,{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":26},"BEHAVIORAL","Participants will perform a combination of aerobic and resistance training for 16 weeks",[9],[32],{"name":33,"affiliation":5,"role":34},"Damon L Swift, Ph.D","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Damon L Swift, Ph.D.","CONTACT","(434) 924-1436","dls3s@virginia.edu",[42],{"facility":5,"status":26,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Charlottesville","Virginia","22901","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-78.47668,38.02931,{"lat":52,"lon":51},[55,56,57,60,62],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":26},{"name":37,"role":34,"phone":26,"phoneExt":26,"email":26},{"name":58,"role":59,"phone":26,"phoneExt":26,"email":26},"Catherine Varney, DO","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":26,"phoneExt":26,"email":26},"Jay Hertel, Ph.D.",{"name":63,"role":59,"phone":26,"phoneExt":26,"email":26},"Sibylle Kranz, Ph.D.",{"type":34,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Damon Swift","Associate Professor","100615923","phase-3-the-effect-of-exercise-and-tirzepatide-on-weight-and-health-outcomes-exer-med-100615923",false,"NCT07298915","The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)","EXER-MED","Inclusion Criteria:\n\n* Men and women 30-65 years of age, postmenopausal women included\n* 27-29.9 with an additional CVD risk factor or 30-40 kg\u002Fm2\n* For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension)\n* Willingness and adequate health to go on weight loss medication\n* The capability and willingness to provide written informed consent\n* Approval of their primary care provider to go on weight loss medication\n\nExclusion Criteria:\n\n* Including but not limited to serious arrhythmias\n* Cardiomyopathy\n* Congestive heart failure\n* Stroke or transient ischemic attacks\n* Peripheral vascular disease\n* Previous history of myocardial infarction or stroke\n* Previous diagnosis or taking medication for type 1 or 2 diabetes, fasting glucose \\>125 mg\u002FdL or HbA1C ≥6.5%\n* Systolic blood pressure \\>160 mmHg and diastolic blood pressure \\>100 mmHg.\n* Hospitalization for mental illness within the past 5 years or currently undergoing treatment for severe mental illness\n* Conditions that can be aggravated or are contraindicated by exercise training\n* Plans to be out of town more than 3 weeks in the next 4 months.\n* Currently pregnant or plans to become pregnant\n* Currently in a diet or exercise program\n* Non-compliance during screening or extreme difficulty in obtaining baseline blood samples\n* Enrolled in a different exercise program\n* Previous weight loss surgery\n* Use of weight loss medication within the last year\n* hypo\u002Fhyper thyroid (medicated or unmedicated)","ALL","30 Years","65 Years",{"count":78,"type":79},24,"ESTIMATED","INTERVENTIONAL",[82],"PHASE3","This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity.\n\nThe main questions it will answer includes:\n\n* Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone\n* Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life\n\nParticipants will:\n\n* Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician\n* (Exercise group only) Will perform exercise \\~3 times a week at the University of Virginia). Walking on a treadmill and resistance training\n* Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures",[85],"Obesity & Overweight",[87,88,9,89,90,91,92],"Obesity","Overweight","aerobic","resistance training","GLP-1","Weight loss","NOT_YET_RECRUITING","2026-05-02",{"date":96,"type":97},"2026-05-06","ACTUAL",{"date":99,"type":79},"2026-08",{"date":101,"type":79},"2027-06",{"name":5,"class":6},1]